Real-World Immunotherapy Study for Pan-Cancer Lymph Node Metastases, 5000+ Patients
Summary
NIH registered a new observational study (NCT07540377) on ClinicalTrials.gov evaluating immunotherapy efficacy for pan-cancer lymph node metastases. The single-center, retrospective study at Sun Yat-sen Memorial Hospital plans to enroll at least 5000 patients treated with immune checkpoint inhibitors. Researchers will assess objective response rates at both primary tumor and metastatic lymph node levels, and explore whether beta-blocker use during immunotherapy affects treatment outcomes.
What changed
NIH added a new clinical trial registration for an observational study evaluating immunotherapy efficacy across multiple cancer types with lymph node metastases. The study will analyze TNM staging changes and objective response rates before and after immune checkpoint inhibitor treatment, and compare outcomes between patients using beta-blockers during immunotherapy and those not using them.
Healthcare providers, clinical investigators, and oncology researchers conducting or analyzing real-world immunotherapy data should note this study's scope and methodology. The findings may inform future immunotherapy protocols for patients with lymph node metastases across different solid tumor types.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Real-World Study on Efficacy and Influencing Factors of Immunotherapy for Pan-Cancer Lymph Node Metastases.
Observational NCT07540377 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
Lymph node metastasis is a key stage of malignant tumor progression and a core factor affecting the efficacy of immunotherapy. The therapeutic response of lymph node metastases to immune checkpoint inhibitors (ICIs) varies significantly among different cancer types, and the underlying regulatory mechanisms remain unclear. This single-center, retrospective observational study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University (Approval No.: SYSKY-2026-278-01). We plan to enroll no less than 5000 patients with pan-cancer lymph node metastasis who received ICI therapy in our hospital. The efficacy of primary tumors (T) and metastatic lymph nodes (N) before and after immunotherapy will be evaluated based on TNM staging changes, and the objective response rate (ORR) at both levels will be calculated. Patients will be divided into two groups according to the use of β-blockers during immunotherapy to compare the ORR differences, and explore the clinical factors affecting the efficacy of immunotherapy for pan-cancer lymph node metastases. This study aims to provide evidence-based medical basis for formulating individualized immunotherapy strategies for pan-cancer lymph node metastasis.
Conditions: Malignant Solid Tumors With Lymph Node Metastasis
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.